Comparative Pharmacology
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE versus ETRAFON A.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHLORPROMAZINE HYDROCHLORIDE versus ETRAFON A.
CHLORPROMAZINE HYDROCHLORIDE vs ETRAFON-A
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Antagonizes dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histamine H1, muscarinic, and serotonin receptors.
ETRAFON-A is a combination of perphenazine (a typical antipsychotic) and amitriptyline (a tricyclic antidepressant). Perphenazine blocks dopamine D2 receptors, while amitriptyline inhibits serotonin and norepinephrine reuptake.
25-100 mg orally or intramuscularly every 4-6 hours; maximum 2 g/day orally or 1 g/day intramuscularly.
Etrafon-A (perphenazine 4 mg/amitriptyline 10 mg) is not FDA-approved; typical dosing per manufacturer: 1 tablet 3-4 times daily, up to 4 tablets/day. Route: oral.
None Documented
None Documented
Terminal elimination half-life 30 ± 14 hours (range 20–70 hours); clinical context: requires multiple daily dosing in acute agitation, but long-acting IM formulations (not chlorpromazine) available; half-life increases with age and hepatic impairment.
Terminal elimination half-life: 18-36 hours (mean 24 h); context: in elderly or hepatic impairment may extend beyond 48 h, requiring dose adjustment.
Primarily hepatic metabolism; renal excretion accounts for ~20% as unchanged drug and metabolites, with ~6% unchanged; biliary/fecal excretion ~80%, mainly as metabolites.
Renal: 50-60% as unchanged drug and metabolites (primarily glucuronide conjugates); Biliary/Fecal: 30-40%; up to 10% excreted via sweat/saliva.
Category C
Category C
Antipsychotic
Antipsychotic/Antidepressant Combination